Mutation landscape in melanoma patients clinical implications of heterogeneity of BRAF mutations

Rare BRAF mutations in melanoma patients: implications for molecular testing in clinical practice

(2013) L Heinzerling et al.   BRITISH JOURNAL OF CANCER

Identification of Multiple Mechanisms of Resistance to Vemurafenib in a Patient with BRAFV600E-Mutated Cutaneous Melanoma Successfully Rechallenged after Progression

(2013) E. Romano et al.   CLINICAL CANCER RESEARCH

Resistance to BRAF-targeted therapy in melanoma

(2013) Ryan J. Sullivan et al.   EUROPEAN JOURNAL OF CANCER

Multisite Analytic Performance Studies of a Real-Time Polymerase Chain Reaction Assay for the Detection ofBRAFV600E Mutations in Formalin-Fixed, Paraffin-Embedded Tissue Specimens of Malignant Melanoma

(2012) Steven Anderson et al.   ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE

BRAF mutation analysis of only one metastatic lesion can restrict the treatment of melanoma: a case report

(2012) E. Richtig et al.   BRITISH JOURNAL OF DERMATOLOGY

Distinguishing Clinicopathologic Features of Patients with V600E and V600K BRAF-Mutant Metastatic Melanoma

(2012) A. M. Menzies et al.   CLINICAL CANCER RESEARCH

BRAF/NRASMutation Frequencies Among Primary Tumors and Metastases in Patients With Melanoma

(2012) Maria Colombino et al.   JOURNAL OF CLINICAL ONCOLOGY

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

(2012) Axel Hauschild et al.   LANCET

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

(2012) Marco Gerlinger et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intra- and Inter-Tumor Heterogeneity of BRAFV600EMutations in Primary and Metastatic Melanoma

(2012) Molly Yancovitz et al.   PLoS One

Routine Multiplex Mutational Profiling of Melanomas Enables Enrollment in Genotype-Driven Therapeutic Trials

(2012) Christine M. Lovly et al.   PLoS One

Polyclonality of BRAF mutations in primary melanoma and the selection of mutant alleles during progression

(2011) J Lin et al.   BRITISH JOURNAL OF CANCER

Spectrum of KIT/PDGFRA/BRAF mutations and Phosphatidylinositol-3-Kinase pathway gene alterations in gastrointestinal stromal tumors (GIST)

(2011) Marc Daniels et al.   CANCER LETTERS

Prognostic and Clinicopathologic Associations of OncogenicBRAFin Metastatic Melanoma

(2011) Georgina V. Long et al.   JOURNAL OF CLINICAL ONCOLOGY

Multiplex Mutation Screening by Mass Spectrometry

(2011) Carol Beadling et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032

(2010) Jill C Rubinstein et al.   Journal of Translational Medicine

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE